ECOG-ACRIN BY THE NUMBERS

Loading Quotes...

Announcements

Deadline for NCI-ComboMATCH laboratory applications extended to 09/30

June 2020 Member Newsletter now available

Read our new Advocacy Blog posts on treatment de-escalation

Latest information about the Fall 2020 Group Meeting 

Don’s miss the first-quarter 2020 TMIST Study Updates 

Question about COVID19? Send an email

Access content from the April 7 COVID-19 Virtual Town Hall

 

Latest News 

Results from InterAAct (EA2133), the first randomized trial for inoperable anal cancer, suggest that carboplatin-paclitaxel become the standard treatment for these patients (Journal of Clinical Oncology). Cathy Eng, MD (Vanderbilt U), led the worldwide trial in the US. Al B. Benson, III (Northwestern U) co-chairs the Anal Cancer Working Group of the International Rare Cancers Initiative. June 18, 2020 Read Press Release

Our latest Advocacy Blog is out. This issue explores the concept of de-escalation, which is an effort to reduce the intensity of cancer treatment without sacrificing efficacy. We also remember Valerie Guild, a tireless advocate for patients with melanoma. June 12, 2020 Advocacy Blog 

 

There is little chance of palbociclib reducing the risk of recurrence for women with HR+, HER2- early breast cancer, according to an update from PALLAS, the international breast cancer study. May 29, 2020 Read Press Release

 

Patients with tumors harboring aberrations in the fibroblast growth factor receptor (FGFR) pathway were treated with AZD4547, an oral FGFR1-3 inhibitor, in Arm W of the NCI-MATCH precision medicine trial. Journal of Clinical Oncology May 28, 2020 Read Article

 

Surgery and radiation do not extend survival in women who present with a diagnosis of breast cancer that is already in an advanced stage (stage IV). Lead investigator Seema A Khan, MD (Northwestern University) will present the results of the E2108 randomized phase 3 trial at the ASCO 2020 plenary session. May 28, 2020 Read More

 

Carfilzomib does not improve outcomes in newly diagnosed myeloma compared to bortezomib. Data from the ENDURANCE (E1A11) randomized phase 3 trial will be presented at the ASCO 2020 plenary session by lead investigator Shaji Kumar, MD (Mayo Clinic). May 28, 2020 Read More

 

The phase 2 trial PrE0505 shows durvalumab added to standard chemotherapy improved overall survival in mesothelioma. Lead investigator Patrick Forde, MD (Johns Hopkins University) will present the results in an oral presentation at ASCO 2020. Read press release on PrECOG website May 20, 2020

 

TAILORx sheds light on cognitive decline in early-stage breast cancer. MedWire News May 19, 2020

 

Trial validates a less intense treatment for HPV-related throat cancer. Article on the randomized phase 2 trial E3311. Medical Xpress May 14, 2020 

 

 

Looking for more (older) news coverage? Visit the News and Info section and the TMIST Press Center.

Group Meeting Highlight

YouTube Highlights

View our YouTube channel for these and other videos:

  • EA8143/PROSPER RCC Clinical Trial for Renal Cell Carcinoma

  • Spring 2020 Virtual Town Hall on COVID-19 
     
  • Strategies to Include Minority Women in the TMIST Breast Cancer Screening Trial

Acknowledgments

Welcome

Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.

The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.

We look forward to sharing our research and partnering with you, as we reshape the future of patient care.

 

Robert L. Comis, MD
Group Co-Chair


Mitchell D. Schnall, MD, PhD
Group Co-Chair
img img
img
img